Bone News and Research

RSS

$Women ages 65-69 with hip fracture more likely to die within a year$

Women ages 65-69 with hip fracture more likely to die within a year

Women ages 65-69 who break a hip are five times more likely to die within a year than women of the same age who don't break a hip, according to a Kaiser Permanente Center for Health Research study funded by the National Institutes of Health and published online today in the Archives of Internal Medicine.

27 Sep 2011

Researchers identify frequent SF3B1 gene mutation in myelodysplasia

A genomic study of chronic blood cancer - a precursor to leukaemia - has discovered gene mutations that could enable diagnosis using only a blood test, avoiding the need for an invasive and painful bone marrow biopsy.

27 Sep 2011

Asuragen announces data from Signature LTx v2.0 clinical study on leukemia

Asuragen, Inc. announced today that data from a study evaluating its Signature LTx v2.0, a CE-marked IVD test, for the multiplex detection of fusion transcripts associated with ALL, AML and CML leukemia, will be presented at the upcoming Planet XMAP Europe being held September 28 - 29, 2011 in Vienna, Austria.

27 Sep 2011

Zoledronic acid may extend survival in older breast cancer patients

A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds.

27 Sep 2011

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.

26 Sep 2011

Zoledronic acid may benefit post-menopausal women with breast cancer

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

Ibandronate controls pain in prostate cancer patients with bone metastases

Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Zometa bone drug trial in post-menopausal women with breast cancer

Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients.

26 Sep 2011

First Radium-223 Chloride Phase III study in prostate cancer

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Gamma radiation could toughen up plastic prosthetic joints

A blast of gamma radiation could toughen up plastic prosthetic joints to make them strong enough to last for years, according to researchers in China writing in the current issue of the International Journal of Biomedical Engineering and Technology.

23 Sep 2011

Corgenix fiscal 2011 net sales decrease to $7,941,576

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.

23 Sep 2011

InSightec's ExAblate Neuro system may treat chronic brain disorders

InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that its investigational ExAblate(R) Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

22 Sep 2011

NIH-funded project to develop new class of tissue regeneration therapeutics

The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.

22 Sep 2011

African Americans more likely than Caucasians to develop and die from lung cancer

Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer.

21 Sep 2011